Carbonic acid, 1,1-dimethylethyl pentafluorophenyl ester | 62631-36-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Carbonic acid, 1,1-dimethylethyl pentafluorophenyl ester
• 英文别名: tert-butyl (2,3,4,5,6-pentafluorophenyl) carbonate
• CAS: 62631-36-1
• 化学式: C₁₁H₉F₅O₃
• 分子量: 284.18
• InChiKey: JMKGTCOQBMMCKJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  Carbonic acid, 1,1-dimethylethyl pentafluorophenyl ester 、 溶剂黄146 以90%的产率得到
  参考文献：
  名称：

  Breslav Michael, Doviborov Nikolay, Naider Fred, J. Chem. Res. Synop, (1994) N 9, S 362-363

  摘要：

  DOI：
• 作为产物：
  描述：

  五氟苯酚 、 二碳酸二叔丁酯 以80%的产率得到
  参考文献：
  名称：

  Breslav Michael, Doviborov Nikolay, Naider Fred, J. Chem. Res. Synop, (1994) N 9, S 362-363

  摘要：

  DOI：

文献信息

• [EN] PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH PATHOLOGICAL THROMBUS FORMATION<br/>[FR] DÉRIVÉS DE LA PYRIDINE ET LEUR UTILISATION DANS LE TRAITEMENT D'ÉTATS ASSOCIÉS À LA FORMATION D'UN THROMBUS PATHOLOGIQUE
  申请人：SANOFI SA

  公开号：WO2013171316A1

  公开（公告）日：2013-11-21

  The present invention relates to compounds of the formula (I), wherein the residues R1 to R6, V, G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds for use in the treatment of diverse disorders, for example cardiovascular disorders like thromboembolic diseases or restenoses. The compounds of the invention are effective antagonists of the platelet LPA receptor LPAR5 (GPR92) and can in general be applied in conditions in which an undesired activation of the platelet LPA receptor LPAR5, the mast cell LPA receptor LPAR5 or the microglia cell LPA receptor LPAR5 is present, or for the cure or prevention of which an inhibition of the platelet, mast cell or microglia cell LPA receptor LPAR5 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in medicaments, and pharmaceutical compositions comprising them.

  本发明涉及具有以下式（I）的化合物，其中残基R1至R6，V，G和M具有索引中所示的含义。式I的化合物是用于治疗各种疾病的有价值的药理活性化合物，例如心血管疾病，如血栓栓塞疾病或再狭窄。该发明的化合物是血小板LPA受体LPAR5（GPR92）的有效拮抗剂，通常可应用于存在血小板LPA受体LPAR5、肥大细胞LPA受体LPAR5或微胶质细胞LPA受体LPAR5的不良激活情况，或用于治疗或预防需要抑制血小板、肥大细胞或微胶质细胞LPA受体LPAR5的情况。此外，本发明还涉及制备式I化合物的方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的药物组合物。
• [EN] PYRAZOLE DERIVATIVES AND THEIR USE AS LPAR5 ANTAGONISTS<br/>[FR] DÉRIVÉS DE PYRAZOLE ET LEUR UTILISATION COMME ANTAGONISTES DE LPAR5
  申请人：SANOFI SA

  公开号：WO2013171317A1

  公开（公告）日：2013-11-21

  The present invention relates to compounds of the formula (I), wherein theresidues R1 to R5, V, G and M have the meanings indicated in the claims. The compounds of the formula (I) are valuable pharmacologically active compounds for use in thetreatmentof diverse disorders, for example cardiovascular disorders like thromboembolic diseases or restenoses. The compounds of the invention are effective antagonists of the platelet LPA receptor LPAR5 (GPR92) and can in general be applied in conditions in which an undesired activation of the platelet LPA receptor LPAR5, the mast cell LPA receptor LPAR5 or the microglia cell LPA receptor LPAR5 is present or for the cure or prevention of which an inhibition of the platelet, mast cell or microglia cell LPA receptor LPAR5 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula (I), their use, in particular as active ingredients in medicaments, and pharmaceutical compositions comprising them.

  本发明涉及公式（I）的化合物，其中残基R1至R5、V、G和M具有所述权利要求中指示的含义。公式（I）的化合物是有价值的药理活性化合物，可用于治疗各种疾病，例如心血管疾病，如血栓栓塞病或再狭窄。本发明的化合物是血小板LPA受体LPAR5（GPR92）的有效拮抗剂，通常可应用于存在血小板LPA受体LPAR5、肥大细胞LPA受体LPAR5或微胶质细胞LPA受体LPAR5的不良激活情况或预防或治愈需要抑制血小板、肥大细胞或微胶质细胞LPA受体LPAR5的情况。本发明还涉及制备公式（I）化合物的方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的制药组合物。
• Pyrazole Derivatives And Their Use As LPAR5 Antagonists
  申请人：SANOFI

  公开号：US20150141477A1

  公开（公告）日：2015-05-21

  The present invention relates to compounds of the formula (I), wherein the residues R 1 to R 5 , V, G and M have the meanings indicated in the claims. The compounds of the formula (I) are valuable pharmacologically active compounds for use in the treatment of diverse disorders, for example cardiovascular disorders like thromboembolic diseases or restenoses. The compounds of the invention are effective antagonists of the platelet LPA receptor LPAR5 (GPR92) and can in general be applied in conditions in which an undesired activation of the platelet LPA receptor LPAR5, the mast cell LPA receptor LPAR5 or the microglia cell LPA receptor LPAR5 is present or for the cure or prevention of which an inhibition of the platelet, mast cell or microglia cell LPA receptor LPAR5 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula (I), their use, in particular as active ingredients in medicaments, and pharmaceutical compositions comprising them.

  本发明涉及式(I)化合物，其中残基R1至R5、V、G和M具有所述权利要求中指示的含义。式(I)化合物是有价值的药理活性化合物，可用于治疗多种疾病，例如心血管疾病，如血栓栓塞疾病或再狭窄。本发明的化合物是血小板LPA受体LPAR5（GPR92）的有效拮抗剂，通常可应用于存在血小板LPA受体LPAR5、肥大细胞LPA受体LPAR5或微胶质细胞LPA受体LPAR5的不良激活情况或治疗或预防需要抑制血小板、肥大细胞或微胶质细胞LPA受体LPAR5的情况。本发明还涉及制备式(I)化合物的方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的制药组合物。
• QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS
  申请人：Nazaré Marc

  公开号：US20100135999A1

  公开（公告）日：2010-06-03

  The present invention relates to compounds of the formula I, in which R 1 ; R 2 ; R 3 ; R 4 ; R 5 ; R 6 ; Z; A; B; E; X; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及公式I的化合物，其中R1; R2; R3; R4; R5; R6; Z; A; B; E; X; Q; J; V; G和M具有所述声明中指示的含义。公式I的化合物是有价值的药理活性化合物。它们对血小板具有强烈的抗聚集作用，从而具有抗血栓作用，适用于治疗和预防心血管疾病，如血栓栓塞病或再狭窄。它们是血小板ADP受体P2Y12的可逆拮抗剂，通常适用于存在不良激活血小板ADP受体P2Y12的情况，或者治愈或预防需要抑制血小板ADP受体P2Y12的情况。此外，本发明还涉及制备公式I化合物的方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的制药制剂。
• Pyridine Derivatives And Their Use In The Treatment Of Conditions Associated With Pathological Thrombus Formation
  申请人：SANOFI

  公开号：US20150141471A1

  公开（公告）日：2015-05-21

  The present invention relates to compounds of the formula (I), wherein the residues R 1 to R 6 , V, G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds for use in the treatment of diverse disorders, for example cardiovascular disorders like thromboembolic diseases or restenoses. The compounds of the invention are effective antagonists of the platelet LPA receptor LPAR5 (GPR92) and can in general be applied in conditions in which an undesired activation of the platelet LPA receptor LPAR5, the mast cell LPA receptor LPAR5 or the microglia cell LPA receptor LPAR5 is present, or for the cure or prevention of which an inhibition of the platelet, mast cell or microglia cell LPA receptor LPAR5 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in medicaments, and pharmaceutical compositions comprising them.

  本发明涉及式（I）的化合物，其中残基R1至R6、V、G和M具有所述权利要求中指示的含义。式I的化合物是有价值的药理活性化合物，可用于治疗各种疾病，例如心血管疾病，如血栓栓塞疾病或再狭窄。本发明的化合物是血小板LPA受体LPAR5（GPR92）的有效拮抗剂，通常可用于存在血小板LPA受体LPAR5、肥大细胞LPA受体LPAR5或微胶质细胞LPA受体LPAR5的不良激活条件，或者用于治疗或预防需要抑制血小板、肥大细胞或微胶质细胞LPA受体LPAR5的情况。本发明还涉及制备式I化合物的方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的制药组合物。